Once-Weekly Pemvidutide Regimen for Weight and Lipid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacologic interventions for weight loss and lipid management in overweight and obese individuals are limited by the need for daily dosing, gastrointestinal side effects, and insufficient impact on cardiovascular risk factors, with existing GLP-1R and GCGR agonists showing suboptimal weight reduction and unclear effects on serum lipids.
Innovation Solution
A once-weekly dosing regimen of a dual GLP-1R and GCGR agonist, pemvidutide, administered in a specific pharmaceutical formulation, to achieve significant weight loss and lipid reduction, minimizing gastrointestinal side effects and improving metabolic health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Weight of stationary object
If existing GLP-1R and GCGR agonists are used for weight loss, then weight reduction is achieved, but the impact on cardiovascular risk factors and serum lipids is insufficient
Solution Approach 1:
The patent modifies the molecular structure of GLP-1R and GCGR agonists by incorporating specific amino acid substitutions and lipid modifications to create compounds with enhanced pharmacological properties. These structural parameter changes result in improved weight loss efficacy and, crucially, significant reductions in serum lipids and cardiovascular risk factors, thereby resolving the contradiction between weight reduction and cardiovascular impact.
Solution Approach 2:
The invention develops dual-acting agonist molecules that simultaneously target both GLP-1R and GCGR receptors with balanced efficacy. This composite pharmacological approach, where a single molecule engages multiple receptor pathways, produces synergistic effects that achieve superior weight loss while also improving lipid profiles and cardiovascular parameters, thus addressing both aspects of the contradiction.
2Weight of stationary object
If pharmacologic interventions are administered daily, then weight loss and lipid reduction are achieved, but gastrointestinal side effects occur
Solution Approach 1:
The patent describes once-weekly dosing regimens for the dual agonist compounds, replacing daily administration. This periodic dosing strategy maintains therapeutic efficacy for weight loss and lipid reduction while significantly reducing gastrointestinal side effects. The extended dosing interval allows the gastrointestinal tract to recover between treatments, minimizing adverse effects while preserving metabolic benefits.
Solution Approach 2:
The invention modifies the pharmacokinetic parameters of the agonists through structural optimization, achieving prolonged half-life and sustained receptor activation. This enables effective weight loss and lipid management with once-weekly dosing rather than daily administration, thereby reducing the frequency of gastrointestinal side effects while maintaining therapeutic benefit.
3Weight of stationary object
If weight loss is achieved through conventional approaches, then body weight is reduced, but lean body mass is lost along with fat mass
Solution Approach 1:
The patent describes dual agonist compounds that differentially affect fat mass and lean body mass through simultaneous activation of GLP-1R and GCGR pathways. The GCGR component specifically promotes lipolysis and fat oxidation, while the GLP-1R component provides appetite suppression and metabolic benefits. This localized metabolic effect preferentially targets fat mass while preserving lean body mass, resolving the contradiction between overall weight loss and lean mass preservation.
4Weight of stationary object
If multiple pharmacologic drugs are used for weight loss, then weight reduction is achieved, but the options are limited and compliance is difficult
Solution Approach 1:
The invention combines two separate pharmacological actions (GLP-1R agonism and GCGR agonism) into a single dual-acting molecule. This merged compound provides both appetite suppression and increased energy expenditure effects in one agent, eliminating the need for multiple separate medications. The once-weekly dosing regimen further simplifies administration, significantly improving patient compliance while maintaining effective weight loss.
Data Source
AI summary
This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of chronic weigh management and/or reducing serum lipids in a subject in need thereof with one or more co-morbidities using a pharmaceutical dosage formulation comprising a peptide product according to SEQ ID NO: 1, or peptide product that is at least 80% identical to a peptide of SEQ ID NO: 1.